HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study.

Abstract
Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test.
AuthorsJosé Illnait, Gladys Castaño, Ernesto Alvarez, Lilia Fernández, Rosa Mas, Sarahí Mendoza, Rafael Gamez
JournalAngiology (Angiology) 2008 Jun-Jul Vol. 59 Issue 3 Pg. 269-77 ISSN: 1940-1574 [Electronic] United States
PMID18388038 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Fatty Alcohols
  • Lipids
  • Platelet Aggregation Inhibitors
  • policosanol
  • Aspirin
Topics
  • Adult
  • Aged
  • Aspirin (administration & dosage, adverse effects)
  • Double-Blind Method
  • Drug Administration Schedule
  • Exercise Test
  • Fatty Alcohols (administration & dosage, adverse effects)
  • Female
  • Humans
  • Intermittent Claudication (blood, drug therapy, physiopathology)
  • Lipids (blood)
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
  • Recovery of Function
  • Treatment Outcome
  • Walking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: